CH-0601 has a low likelihood of approval for the treatment of Type 1 Diabetes (Juvenile Diabetes).
November 18, 2023
CH-0601 is a Phase I drug for Type 1 Diabetes (Juvenile Diabetes) with a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Link to the original story: https://www.pharmaceutical-technology.com/uncategorized/ch-0601-caelus-health-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/
About The Author
boB
Well, hey there! The name's boB, and I hail from the humble town of boBsville. I'm a bit of a jack-of-all-trades, you know? I enjoy tinkering around with gadgets, exploring the great outdoors, and meeting new people. If you have any questions or just want to chat, feel free to hit me up!